Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$17,500.00

Development of an in Vivo Assay for Liver Function Assessment Using Near-Infrared Fluorescent Liposomes

EF 2022-23

Résumé
Recent estimates point to approximately two million deaths per year worldwide due to liver disease, particularly liver cirrhosis and acute liver failure. Liver cirrhosis rates are increasing because of obesity which often leads to steatosis and cirrhosis. Liver diagnostics promise to enable rapid diagnosis and staging of liver disease, as well as the assessment of treatment responses, and would enable personalized medicine in liver disease. However, currently used liver tests are not capable of assessing liver function. Liver biopsy is the gold standard, but this test is invasive and suffers from sampling errors. Biochemical parameters of the liver such as liver enzymes (AST, ALT), that are released when hepatocytes are damaged, are most commonly used. These tests have low specificity and selectivity, however. Therefore, the ultimate aim of this project is to develop a clinically viable liver function test.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486369
Name
Guirguis Natalie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of an in Vivo Assay for Liver Function Assessment Using Near-Infrared Fluorescent Liposomes
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Diagnostics; Hepatocytes; Imaging; Liposomes; Liver Cirrhosis; Near-Infrared Fluorescence
Abstract
Recent estimates point to approximately two million deaths per year worldwide due to liver disease, particularly liver cirrhosis and acute liver failure. Liver cirrhosis rates are increasing because of obesity which often leads to steatosis and cirrhosis. Liver diagnostics promise to enable rapid diagnosis and staging of liver disease, as well as the assessment of treatment responses, and would enable personalized medicine in liver disease. However, currently used liver tests are not capable of assessing liver function. Liver biopsy is the gold standard, but this test is invasive and suffers from sampling errors. Biochemical parameters of the liver such as liver enzymes (AST, ALT), that are released when hepatocytes are damaged, are most commonly used. These tests have low specificity and selectivity, however. Therefore, the ultimate aim of this project is to develop a clinically viable liver function test.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Guirguis, Natalie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~